DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
520 patients (estimated)
Sponsors
GlaxoSmithKline
Tags
Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA)
Trial Type
Treatment
Last Update
23 hours ago
SparkCures ID
2027
NCT Identifier
NCT06679101

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.